METRONOMIC DOSING OF CYCLOPHOSPHAMIDE AND THROMBOSPONDIN LEVELS IN IDIOPATHIC NE

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。本研究的目的是探讨肾病综合征(NS)患者血浆凝血酶敏感蛋白-1(TSP)水平与节律剂量环磷酰胺(CTX)疗效的关系。目的：探讨肾病综合征患者血浆TSP-1水平与CTX治疗反应的相关性。在这项初步研究中，我们将从激素抵抗、类固醇依赖或频繁复发的NS患者中获取血清，这些患者即将开始为期12周的CTX疗程。我们将在注射环磷酰胺前获取血清，第二次在中点，并在12周疗程结束时获取血清。我们的假设是，肾病综合征患者在接受CTX治疗后获得缓解后，他们的TSP水平将会增加，这表明CTX的有益作用是通过TSP-1介导的。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objective of this study is to evaluate the association between thrombospondin-1 (TSP) levels and response to metronomic dose cyclophosphamide (CTX) in patients with Nephrotic Syndrome (NS). Specific Aim: To determine whether TSP-1 levels in patients with NS correlate with response to therapy with CTX. In this pilot study, we will obtain serum from subjects with steroid resistant, steroid dependent, or frequently relapsing NS who are about to initiate a 12 week course of CTX. We will obtain serum prior to initation of CTX, a second time at the midpoint, and at the the completion of the 12 week course. Our hypothesis is that subjects with Nephrotic Syndrome who achieve remission with CTX will show increases in their levels of TSP, suggesting that the beneficial effect of CTX is mediated by TSP-1.